ARTICLES

img

Quality by Design (QbD) in Pharma: Principles and Applications

The pharmaceutical industry is evolving rapidly, with increasing regulatory demands, complex drug formulations, and the rise of biologics challenging traditional manufacturing methods. <br> How can companies stay ahead while ensuring efficiency, quality, and compliance? <br><br> This white paper delves into Quality by Design (QbD) and Design of Experiments (DoE)—two transformative methodologies that are revolutionising drug development. <br><br> Learn how top pharmaceutical companies like Strides Pharma leverage these approaches to enhance product quality, reduce risks, optimise processes, and streamline regulatory compliance. <br><br> Get insights on: <br> ✔️ QbD’s shift from reactive testing to built-in quality <br> ✔️ DoE’s role in faster, smarter drug formulation <br> ✔️ A real-world case study on arthritis medication development <br>

Read More
img

The ESG Shift in Pharma: From Compliance to Competitive Advantage

How does a pharma company stay ahead while serving global health needs? By making sustainability, ethics, and governance a core priority.

Read More
img

Beyond the Pharma Product Pipeline: Inside Strides Pharma’s Approach to Portfolio Development

Everyone sees the product launch. Few see the decisions that made it possible.

Read More
img

Waves of opportunity: Riding APAC's Currents of Fragmentations, Collaborations, and Change

The Asia-Pacific (APAC) pharmaceutical market, already worth over USD 330 billion in 2024, is entering a new phase of maturity.

Read More
img

Inside the U.S. OTC Opportunity: How Agility, Timing, and Trust Drive Sustainable Growth

The U.S. over-the-counter (OTC) pharmaceutical market is expanding, but not without complexity. Valued at USD 42.4 billion in 2024, it is projected to grow at around 4.8 per cent CAGR through 2034, reflecting steady but margin-tightened growth.

Read More
img

Evolution of Generic Medicines: Strategic Insights for the Future

Set to skyrocket from $367.1 billion in 2023 to $628 billion by 2032, the generic drug market is experiencing a boom! What's fueling this rapid expansion? A mix of factors: patent expirations, a rise in chronic diseases, and increased research investments.

Read More
img

Strides Recognized Among Leading Global ESG Performers

Enters S&P yearbook in 1st year of participation

Read More
img

Pharma Manufacturing Quality: Standards for Operational Excellence

The pharmaceutical industry is facing an alarming trend: a dramatic increase in drug recalls. In 2022 alone, defective pharmaceutical units hit a five-year high, with January 2023 marking a significant spike in recalls– over 11.88 million units impacted due to critical deviations from Good Manufacturing Practices (GMP).

Read More